chronic myelomonocytic leukaemia (CMML) | Page 2 | Aplastic Anemia & MDS International Foundation

chronic myelomonocytic leukaemia (CMML)

Shannon McCurdy, MD

McCurdy, Shannon
Assistant Professor of Medicine
University of Pennsylvania

Shannon McCurdy, MD is Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and is employed by Penn Medicine. Dr. McCurdy is board certified in Internal Medicine and Medical Oncology. She is an active researcher and works with the Bone Marrow and Stem Cell Transplant Program, the Hematological Malignancies (Blood Cancer) Program and the Leukemia Program. 

Sarah Bannon, MS, CGC

Bannon, Sarah
Senior Genetic Counselor
University of Texas MD Anderson Cancer Center

Sarah Bannon is a Senior Genetic Counselor in the Department of Clinical Cancer Genetics at the UT MD Anderson Cancer Center. Her clinical responsibilities include providing risk assessment and genetic counseling services to individuals at risk for an inherited predisposition to hematologic malignancies (leukemia). She is the Genetic Counselor for the Hereditary Hematologic Malignancies Clinic (HHMC).

Mary K. Hughes, MS, RN, CNS, CT

Hughes, Mary
Outpatient, Clinical Nurse Specialist
University of Texas MD Anderson Cancer Center

Mary K. Hughes, MS, RN, CNS, CT, is a Outpatient, Clinical Nurse Specialist with the University of Texas MD Anderson Cancer Center Psychiatry Department where she works with a team of mental health professionals to support patients, families and caregivers from diagnosis to treatment to survivorship. 

SNS-301 Monotherapy in High Risk MDS and CMML

This phase 2, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of intradermally-delivered SNS-301 delivered using the 3M® hollow microstructured transdermal system (hMTS) device in patients with ASPH+ high risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial population consists of high risk ≥ Intermediate Risk-3 (IR-3) MDS and CMML-2.

omparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

This phase II trial studies how well 3 different drug combinations prevent graft versus host disease (GVHD) after donor stem cell transplant. Calcineurin inhibitors, such as

National March for Marrow 2020 - Virtual Walk/5K

We've gone VIRTUAL!
With the health and well-being of our patients, family members, friends and faculty as our top priority, AAMDSIF is holding our National March for Marrow as a VIRTUAL WALK! 

Event Date: 
Sat, 07/18/2020
Community Event Type: 

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)

The purpose of this study is to determine whether the combination of pevonedistat and